ReviewLipids in health and disease2026
Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk.
Review in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Total Flavonoids fromAntioxidants (Basel, Switzerland) · 2026Article
- Exploring the interplay between systemic immune-inflammatory response, nutritional patterns, and metabolic health in MAFLD.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), whose pathogenesis involves complex multi-organ crosstalk and the remodeling of the hepatic immune microenvironment, constitutes a major global health challenge. The latest research indicates that the dysregulation of the AMPK-SREBP1-FASN (ASF) signaling axis plays a core role in mediating abnormal fatty acid synthesis and the accumulation of lipotoxic metabolites in MASLD, serving as a key molecular hub linking hepatic metabolic disorders with immune inflammatory responses. Dysregulated ASF axis and the subsequent lipotoxic products not only directly impair hepatocellular organelle function but also, by disrupting intercellular communication and reprogramming immune cell and hepatocyte metabolism, drive a self-perpetuating “metabolic-immune” vicious cycle. This cycle propels disease progression toward fibrosis and extrahepatic complications. However, how ASF axis dysregulation specifically reshapes the hepatic immune landscape remains to be systematically elucidated. This review aims to systematically describe the crucial role of the ASF axis in MASLD. First, it outlines the pivotal function of this axis in multi-system interactions and the disruption of the hepatic immune microenvironment. It then provides an in-depth analysis of the regulatory mechanisms and functional characteristics of the ASF axis in both hepatocytes and immune cells. Furthermore, it explores the molecular mechanisms by which ASF axis dysregulation exacerbates lipotoxicity through promoting CD36-dependent lipid uptake and dissects how lipotoxicity impairs hepatocellular function and hepatic immune homeostasis in MASLD. Finally, the review summarizes potential therapeutic strategies targeting the ASF axis, which are designed to disrupt the metabolic-immune vicious cycle and restore systemic homeostasis. By offering an integrated perspective, this review seeks to advance the understanding of the immune-metabolic pathogenesis of MASLD and to establish a theoretical foundation for developing precise therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.